Don't forget to share!

A new approach to the Alzheimer’s disease diagnosis

8 May, 2012

The AD-CSF-Index (Alzheimer’s Disease Cerebrospinal Fluid Index) jointly analyzes decreased levels of beta amyloid (Aβ1-42) and increased levels of tau and phosphorylated tau proteins in cerebrospinal fluid (CSF) of Alzheimer’s disease (AD) patients. The combination of these three protein biomarkers has allowed the researchers, for the first time, to optimize an index representing the observed alterations in the fluid that bathes the brain, and correlate it with a high sensitivity and high specificity AD’s diagnosis.

The AD-CSF-Index is being clinically validated in four European centers: the Hospital Clinic of Barcelona, the Hospital de Sant Pau in Barcelona, the Hôpital Pitié Salpêtrière in Paris, and the Neurological Clinic of the University of Bonn.

“We hope this index will soon be useful for the diagnosis and monitoring of the changes that happen throughout the course of AD’s biological evolution”

Juan Domingo Gispert, researcher.

The study, published in the Revista de Neurología, has been coordinated by José Luis Molinuevo, director of the Alzheimer’s Disease and Cognitive Disorders Unit of the Hospital Clínic of Barcelona, and principal investigator of the Pasqual Maragall Foundation Clinical Research Program; and by Juan Domingo Gispert, Head of Neuroimaging Research at the Pasqual Maragall Foundation.

More information:

A new approach to the Alzheimer’s disease diagnosis with biomarkers: description of the AD-CSF-Index, Rev Neurol. 2012 May 1;54(9):513-22. Molinuevo JL, Gispert JD, Pujol J, Rojas S, Llado A, Balasa M, Antonell A, Sanchez-Valle R, Rami L.